Table 2.
Any Grade And Grade ≥ 3 Adverse Events Reported In The Included Studies In This Meta-Analysis
| Adverse Events | PD-1/PD-L1 inhibitor plus carboplatin-paclitaxel no. (%) | Carboplatin-paclitaxel chemotherapy-based no. (%) | ||
|---|---|---|---|---|
| (n = 713) | (n = 718) | |||
| (n = 79) | Any Grade n(%) | ≥ 3 Grade n(%) | Any Grade n(%) | ≥ 3 Grade n(%) |
| General disorders and administration site conditions | ||||
| Fatigue | 414 (58.06) | 7 (0.98) | 386 (53.76) | 3 (0.42) |
| Anemia | 340 (47.69) | 104 (14.59) | 339 (47.21) | 82 (11.42) |
| Infusion related reaction | 61 (8.55) | 8 (1.12) | 51 (7.10) | 10 (1.39) |
| Decreased appetite | 52 (7.29) | 0 | 43 (5.99) | 0 |
| Weight loss | 35 (4.91) | 2 (0.28) | 27 (3.76) | 3 (0.42) |
| Fever | 14 (1.96) | 0 | 9 (1.25) | 1 (0.14) |
| Generalized Pain | 3 (0.42) | 0 | 5 (0.70) | 1 (0.14) |
| Nervous system disorders | ||||
| Peripheral sensory neuropathy | 344 (48.25) | 9 (1.26) | 346 (48.19) | 6 (0.84) |
| Paresthesia | 17 (2.38) | 2 (0.28) | 26 (3.62) | 1 (0.14) |
| Stroke | 1 (0.14) | 1 (0.14) | 1 (0.14) | 1 (0.14) |
| Vasovagal reaction | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Cardiovascular system disorders | ||||
| Hypertension | 71 (9.96) | 27 (3.79) | 61 (8.50) | 11 (1.53) |
| Supraventricular tachycardia | 0 | 0 | 1 (0.14) | 1 (0.14) |
| Cardiac disorders (other) | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Vascular disorders | ||||
| Pulmonary embolism | 6 (0.84) | 6 (0.84) | 5 (0.70) | 5 (0.70) |
| Thromboembolic event | 6 (0.84) | 1 (0.14) | 2 (0.28) | 0 |
| Hot flashes | 1 (0.14) | 1 (0.14) | 2 (0.28) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Dyspnea | 134 (18.79) | 14 (1.96) | 124 (17.27) | 2 (0.28) |
| Pneumonitis | 5 (0.70) | 2 (0.28) | 3 (0.42) | 1 (0.14) |
| Gastrointestinal disorders | ||||
| Nausea | 330 (46.28) | 7 (0.98) | 294 (40.95) | 5 (0.70) |
| Constipation | 266 (37.31) | 5 (0.70) | 246 (34.26) | 3 (0.42) |
| Diarrhea | 234 (32.82) | 12 (1.68) | 207 (28.83) | 4 (0.56) |
| Vomiting | 86 (12.06) | 5 (0.70) | 54 (7.52) | 5 (0.70) |
| Colitis | 11 (1.54) | 0 | 4 (0.56) | 1 (0.14) |
| Pyrexia | 6 (0.84) | 6 (0.84) | 2 (0.28) | 2 (0.28) |
| Abdominal pain | 7 (0.98) | 2 (0.28) | 3 (0.42) | 0 |
| Pancreatitis | 1 (0.14) | 0 | 4 (0.56) | 0 |
| Mucositis oral | 2 (0.28) | 0 | 3 (0.42) | 0 |
| Ascites | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Hepatic Failure | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Colonic obstruction | 0 | 0 | 1 (0.14) | 1 (0.14) |
| Renal and urinary disorders | ||||
| Urinary tract infection | 4 (0.56) | 4 (0.56) | 7 (0.97) | 5 (0.70) |
| Acute Kidney Injury | 7 (0.98) | 7 (0.98) | 3 (0.42) | 3 (0.42) |
| Urinary tract obstruction | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Bladder infecction | 1 (0.14) | 0 | 1 (0.14) | 0 |
| Skin and subcutaneous tissue disorders | ||||
| Alopecia | 145 (20.34) | 0 | 149 (20.75) | 0 |
| Rash | 125 (17.53) | 7 (0.98) | 77 (10.72) | 4 (0.56) |
| Pruritus | 5 (0.70) | 1 (0.14) | 2 (0.28) | 0 |
| Erythema multiforme | 2 (0.28) | 1 (0.14) | 1 (0.14) | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 191 (26.79) | 3 (0.42) | 203 (28.27) | 3 (0.42) |
| Myalgia | 137 (19.21) | 2 (0.28) | 133 (18.52) | 5 (0.70) |
| Asthenia | 2 (0.28) | 2 (0.28) | 6 (0.84) | 6 (0.84) |
| Muscular weakness | 5 (0.70) | 5 (0.70) | 1 (0.14) | 1 (0.14) |
| Myositis | 2 (0.28) | 0 | 1 (0.14) | 1 (0.14) |
| Bone pain | 1 (0.14) | 0 | 3 (0.42) | 0 |
| Musculoskeletal and connective tissue disorders (other) | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Endocrine system disorders | ||||
| Hypothyroidism | 112 (15.71) | 27 (3.78) | 79 (11.00) | 7 (0.97) |
| Hyperthyroidism | 26 (3.65) | 0 | 11 (1.53) | 0 |
| Adrenal Insuffiency | 4 (0.56) | 0 | 1 (0.14) | 0 |
| Hypophysitis | 2 (0.28) | 2 (0.28) | 0 | 0 |
| Metabolism and nutrition disorders | ||||
| Hypomagnesemia | 52 (7.29) | 0 | 70 (9.75) | 0 |
| Hypokalemia | 12 (1.68) | 0 | 9 (1.25) | 0 |
| Hyperglycaemia | 5 (0.70) | 2 (0.28) | 2 (0.28) | 0 |
| Anorexia | 2 (0.28) | 1 (0.14) | 5 (0.70) | 0 |
| Hypertriglyceridemia | 4 (0.56) | 1 (0.14) | 0 | 0 |
| Hypercalcemia | 2 (0.28) | 0 | 2 (0.28) | 0 |
| Glucose Intolerance | 2 (0.28) | 0 | 0 | 0 |
| Reproductive system and breast disorders | ||||
| Uterine hemorrhage | 4 (0.56) | 0 | 1 (0.14) | 1 (0.14) |
| Pelvic pain | 1 (0.14) | 1 (0.14) | 2 (0.28) | 0 |
| Vaginal hemorrhage | 2 (0.28) | 1 (0.14) | 0 | 0 |
| Reproductive system and breast disorders (other) | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Blood and lymphatic system disorders | ||||
| Neutropenia or Neutrophil count decreased | 154 (21.60) | 110 (15.43) | 172 (23.96) | 104 (14.48) |
| Thrombocytopenia | 137 (19.21) | 20 (2.80) | 106 (14.76) | 9 (1.25) |
| White blood cell decreased | 36 (5.05) | 23 (3.23) | 30 (4.17) | 21 (2.92) |
| Alanine aminotransferase increased | 22 (3.08) | 1 (0.14) | 4 (0.56) | 0 |
| Platelet count decreased | 16 (2.24) | 5 (0.70) | 17 (2.37) | 3 (0.42) |
| Alkaline phosphatase increased | 6 (0.84) | 3 (0.42) | 1 (0.14) | 0 |
| Aspartate aminotransferase increased | 7 (0.98) | 1 (0.14) | 2 (0.28) | 0 |
| Creatinine increased | 4 (0.56) | 0 | 4 (0.56) | 1 (0.14) |
| Gamma-glutamyl transferase increased | 5 (0.70) | 1 (0.14) | 2 (0.28) | 0 |
| Blood bilirubin increased | 2 (0.28) | 1 (0.14) | 0 | 0 |
| Leukocytosis | 0 | 0 | 1 (0.14) | 1 (0.14) |
| Immune system disorders | ||||
| Allergic reaction | 8 (1.12) | 4 (0.56) | 6 (0.84) | 1 (0.14) |
| Immune system disorders (other) | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Infections and infestations | ||||
| Tooth infection | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Wound complication | 1 (0.14) | 1 (0.14) | 0 | 0 |
| Infections and infestations (other) | 5 (0.70) | 2 (0.28) | 2 (0.28) | 0 |